RA Capital Management

Healthcare innovation doesn't just happen on its own. Inventing the future of health takes vision, grit, capital and teamwork. Congratulations to Michael Pehl and the whole Adcendo team on closing an oversubscribed $135 million Series B funding round to support their ongoing efforts to advance their portfolio of antibody-drug conjugates (#ADC's) for the treatment of cancers with high unmet medical needs. RA Capital is proud to continue our support for Adcendo's work. https://lnkd.in/ekReknFN https://lnkd.in/eTtG6KGS

Applications for #Science2Startup are still open! Submit your #startup idea by Dec 2nd for an opportunity to present to top #biotech and #pharma execs, VCs and entrepreneurs. Apply now: https://lnkd.in/dagcYpEc

Congratulations to CEO Sandra Abrevaya, Brian Wallach and the Synapticure Inc. team on closing their $25 million Series A funding round - we look forward to their continued efforts to expand virtual care for neurodegenerative diseases! https://lnkd.in/ggtqWRGY

Great to see Gunnar Esiason, director of patient engagement for RA Capital's Raven (RA Ventures) healthcare incubator speaking at ISPOR—The Professional Society for Health Economics and Outcomes Research EU Conference in Barcelona! #ISPOREurope #ISPORSummit #RWE #RealWorldEvidence #HEOR #HTA #Healthcare https://bit.ly/3YYhyjF

We’ve extended our submission deadline for the 2025 #Science2Startup symposium on May 14th. This is your last chance to share your game-changing startup idea with leading #biotech and #pharma executives, VCs, and entrepreneurs – don’t wait, apply now! Applications are due by Dec. 2nd at midnight: https://lnkd.in/e7bPwMzX

We're excited to support Trace Neuroscience's efforts to develop novel genomic treatments for people living with #ALS and other neurodegenerative diseases. Congratulations to Eric Green and the entire Trace Neuroscience team on their Series A financing! https://lnkd.in/gzKuwz5v

Time is running out! #Science2Startup 2025, on Wednesday, May 14th, is a one-day symposium providing research applicants with a unique opportunity to receive guidance and mentorship from leaders in the biotech field. Submit your application by Friday, November 15th, to pitch your innovative startup ideas to leading #biotech and #pharma experts: https://lnkd.in/e7bPwMzX Don’t miss your chance to apply!

It's been a big week for RA Capital Management portfolio companies, and the news keep coming. This time it's Evommune and Elektrofi! First, congratulations to the Evommune team on their recent close of a $115 million Series C, which we co-led with Sectoral Asset Management. RA Capital Management Partner Derek DiRocco will join the Evommune board, and proceeds from the raise will be used to support the advancement of Evommune's lead clinical programs in chronic urticaria and atopic dermatitis. We look forward to following the team's continued efforts! Next up, congratulations to Chase Coffman and the Elektrofi team on their recent close of a $112.25 million Series C to help establish #Ph3 and commercial-scale GMP manufacturing capacity. The RA Capital team co-led this round with Novo Holdings, Royalty Pharma, SR One Capital Management, and TPG LSI. Read Elektrofi's post here: https://lnkd.in/ghDMDvYN #biotech #innovation

Congratulations to the INNOVENTRIC team on the close of their recent $28.5M Series B, led by RA Capital Management. We look forward to their continued efforts to address tricuspid regurgitation (TR). RA Capital Management's Anurag Kondapalli, a principal on RA Capital's Health Services and Technology (HST) team, said: "We are excited to support INNOVENTRIC as it looks to transform the approach to TR treatment. The strong outcomes from their European first-in-human trial demonstrate the immense potential of their anatomy-agnostic device to treat a broader range of patients who have lacked viable options." Onward! #TR #biotech #Innovation #Healthtech

Congratulations to Marcelo Bigal and the team at Ventus Therapeutics on the successful completion of their Phase 1 for VENT-03, a first-in-class cGAS inhibitor! Some day, their once-daily pill could be a game-changer for #lupus patients and many others with limited treatment options who are suffering from auto-immune diseases. #drugdevelopment #innovation #lupus #autoimmune